deltatrials
Active Not Recruiting PHASE2/PHASE3 INTERVENTIONAL 4-arm NCT02405676

BNHL-2015 for Children or Adolescents in China (BNHL-2015)

Treatment Regimen or Children or Adolescent with Mature B-cell NHL or B-AL in China

Sponsor: Children's Cancer Group, China

Conditions Mature B-cell Non-Hodgkin Lymphoma
Interventions Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone Prednisone,Vincristine, Cyclophosphamide Rituximab
Updated 16 times since 2017 Last updated: Feb 11, 2025 Started: Jan 31, 2015 Primary completion: Dec 31, 2023 Completion: Dec 31, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Mature B-cell Non-Hodgkin Lymphoma and is currently ongoing. Children's Cancer Group, China leads this study, which shows 16 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Jun 2017 · 5 months · monthly snapshot~Jun 2017 – ~Dec 2017 · 6 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Jan 2019 · 7 months · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Jan 2021 · 22 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Sep 2021 · 7 months · monthly snapshot~Sep 2021 – ~Apr 2022 · 7 months · monthly snapshot~Apr 2022 – ~Mar 2023 · 11 months · monthly snapshot~Mar 2023 – ~Oct 2023 · 7 months · monthly snapshot~Oct 2023 – ~Mar 2024 · 5 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – present · 18 months · monthly snapshot

Change History

16 versions recorded

  1. Mar 2025 — Present [monthly]

    Active Not Recruiting PHASE2/PHASE3

  2. Sep 2024 — Mar 2025 [monthly]

    Active Not Recruiting PHASE2/PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  4. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  5. Oct 2023 — Mar 2024 [monthly]

    Active Not Recruiting PHASE2_PHASE3

▶ Show 11 earlier versions

  1. Mar 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  2. Apr 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  3. Sep 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Status: Recruiting → Active Not Recruiting

  4. Feb 2021 — Sep 2021 [monthly]

    Recruiting PHASE2_PHASE3

  5. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2_PHASE3

  6. Mar 2019 — Jan 2021 [monthly]

    Recruiting PHASE2_PHASE3

  7. Jan 2019 — Mar 2019 [monthly]

    Recruiting PHASE2_PHASE3

  8. Jun 2018 — Jan 2019 [monthly]

    Recruiting PHASE2_PHASE3

  9. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE2_PHASE3

  10. Jun 2017 — Dec 2017 [monthly]

    Recruiting PHASE2_PHASE3

  11. Jan 2017 — Jun 2017 [monthly]

    Recruiting PHASE2_PHASE3

    First recorded

Jan 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Children's Cancer Group, China
  • Children's Hospital of Soochow University
  • Nanjing Children's Hospital
  • Qilu Hospital of Shandong University
  • Tianjin Medical University Cancer Institute and Hospital
  • Tongji Hospital
  • West China Second University Hospital
  • Xiangya Hospital of Central South University
Data source: Children's Cancer Group, China

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations